Until now, Perlegen contends, pharmacogenomics has failed to deliver because no one has had the statistical power to show connections. With its whole genome scanning technology, Perlegen aims to prove that it can come up with usable and predictive markers of drug response by inexpensively screening for millions of SNPs and analyzing subsequent patterns--even without any significant biological understanding. The start-up aims to use its technology to help compounds win regulatory approval and more market share than they otherwise could. Perlegen also plans to support in-licensed drug candidates and seek disease genes. It wants a share of drug sales its studies enable, and to leverage all the IP it can capture. Absent its own drug discovery and development program, Perlegen needs partners to provide the compounds and clinical samples with which it can create pharmacogenomic data and secure an FDA imprimatur. Competitors argue that smaller sets of data, informed by a clearer biological understanding, will provide equally effective pharmacogenomic data, cheaper.
t's the rare start-up that begins life with an initial financing
round anywhere close to $100 million. But investors expect great
things from Affymetrix Inc. 's spin-off
Perlegen Sciences Inc. in, of all
places, the field of pharmacogenomics.
Pharmacogenomics specialists have hardly delivered on their promises. There have been some claimed successes, most recently from Millennium Pharmaceuticals Inc....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
